EVIO, Inc. EVIO

Company Overview

EVIO, Inc. (OTC: EVIO) is a cannabis industry services company historically focused on analytical testing, quality assurance, compliance consulting, and scientific support services for regulated cannabis markets in the United States. Public disclosures and historical filings indicate the company operated through accredited laboratory testing facilities and advisory businesses serving cannabis cultivators, processors, dispensaries, and product manufacturers. Its activities were primarily tied to regulatory compliance requirements involving potency analysis, contaminant screening, labeling validation, and product safety testing.

The company evolved from earlier operations under the name Signal Bay, Inc. before rebranding to EVIO, Inc. as part of a strategy to expand its cannabis science and compliance platform. EVIO pursued growth through laboratory acquisitions, licensing arrangements, and regional partnerships in state-regulated cannabis markets. Its strategic positioning centered on being an independent testing and compliance provider in an industry increasingly shaped by mandatory laboratory standards and product traceability requirements. Some operational and financial information is limited or inconsistent across public disclosures, and certain recent business status details are inconclusive based on available public sources.

Business Operations

EVIO historically generated revenue through cannabis analytical testing, laboratory services, consulting, and licensing activities. Its operations included testing for cannabinoid potency, pesticides, residual solvents, heavy metals, microbiological contaminants, and terpene profiles. Public filings and investor materials referenced business units and subsidiaries associated with laboratory operations in multiple regulated U.S. jurisdictions, including Oregon and California. The company also pursued consulting and accreditation support services for cannabis operators navigating evolving state regulations.

The company’s operating model relied on laboratory infrastructure, scientific personnel, testing methodologies, and regulatory certifications or accreditations required under state cannabis programs. EVIO also entered into partnerships and licensing arrangements intended to expand market coverage without directly owning every laboratory location. Historical disclosures referenced relationships with local operators and affiliated laboratories; however, the current operational status of several subsidiaries, partnerships, or previously announced initiatives is difficult to independently verify from recent public information. Data inconclusive based on available public sources.

Strategic Position & Investments

EVIO’s strategy emphasized participation in the expanding regulated cannabis economy through compliance-driven services rather than direct cultivation or retail exposure. The company publicly communicated plans to build a national network of cannabis testing laboratories and compliance solutions businesses. Growth initiatives historically included acquisitions of regional laboratories, development of standardized testing procedures, and expansion into newly legalized state markets where mandatory testing requirements created recurring demand for third-party analytical services.

The company also explored broader cannabis science opportunities involving data analytics, product standardization, and regulatory advisory services. Public disclosures referenced investments in laboratory capacity, accreditation efforts, and regional operating partnerships. Several announced acquisitions and expansion initiatives were tied to changing regulatory conditions and capital availability. Due to limited recent disclosures and varying reporting across market sources, the present status of certain investments, subsidiaries, or strategic initiatives remains inconclusive based on available public sources.

Geographic Footprint

EVIO’s operations were concentrated in the United States, with historical activity primarily in the Western United States, including Oregon, California, and other state-regulated cannabis markets. The company’s headquarters was historically located in Florida, although many operational assets and laboratory activities were tied to western cannabis jurisdictions where testing requirements were more established during the company’s expansion phase.

The company pursued a multi-state operating strategy through direct ownership, licensing, and partnership structures intended to create a broader national laboratory network. Public filings and investor communications indicated interest in expanding into additional legalized cannabis markets as regulatory frameworks matured. There is limited verified evidence of significant international operations or sustained non-U.S. commercial presence.

Leadership & Governance

EVIO’s leadership historically included executives with backgrounds in cannabis operations, public markets, laboratory services, and business development. Founder-related leadership was associated with the company’s earlier identity as Signal Bay, Inc., prior to its transition into EVIO. Public company governance was conducted through a board of directors and executive management structure typical of OTC-listed issuers. Recent executive continuity and governance structure details are not consistently available across current public records.

Key executives identified in historical public disclosures include:

• William Waldrop – Chief Executive Officer
• Melissa Matilla – Chief Financial Officer
• Lori Glauser – Former Chief Executive Officer
• Stephen Schwoebel – Former President and Director

Leadership communications historically emphasized building a scalable cannabis testing platform focused on regulatory compliance, scientific credibility, and expansion into newly legalized jurisdictions. More recent strategic direction and active executive leadership details are inconclusive based on available public sources.